Results 31 to 40 of about 182,433 (270)

[Expert recommendations on the management of adverse reactions in pegylated interferon alpha therapy for chronic hepatitis B]. [PDF]

Zhonghua Gan Zang Bing Za Zhi
Expert Group on the Management of Adverse Reactions in Pegylated Interferon Alpha Therapy for Chronic Hepatitis B.
europepmc   +3 more sources

The impact of metabolic dysfunction-associated steatotic liver disease on the efficacy of pegylated interferon-based therapy in patients with chronic hepatitis B. [PDF]

Front Immunol
Han J, Xu L, Li Y, Wang Z, Zeng M, Gao J, Mi Y, Kuai W, Xiang H, Xu L.   +9 more
europepmc   +3 more sources

NAFLD‐related hepatocellular carcinoma: The growing challenge

Hepatology, EarlyView., 2022
Risk and protective factors for NAFLD‐related hepatocellular carcinoma Abstract Hepatocellular carcinoma (HCC) is a common cause of cancer‐related mortality and morbidity worldwide. With the obesity pandemic, NAFLD‐related HCC is contributing to the burden of disease exponentially.
Pir Ahmad Shah, Rashmee Patil, Stephen A. Harrison   +2 more
wiley   +1 more source

Screening for hepatitis D and PEG-Interferon over Tenofovir enhance general hepatitis control efforts in Brazil. [PDF]

PLoS ONE, 2018
BACKGROUND:Hepatitis D virus (HDV), which requires the presence of hepatitis B virus (HBV), is a deadly yet neglected disease that rapidly leads to liver cancer and disease-induced mortality.
Ashish Goyal, Ethan Obie Romero-Severson
doaj   +1 more source

Traditional and Novel Virologic Markers for Functional Cure and HBeAg Loss with Pegylated Interferon in Chronic Hepatitis B: A Systematic Review and Meta-analysis. [PDF]

J Clin Transl Hepatol
Zhang Y, Wang LF, Chen J, Nguyen MH, Zheng Q.   +4 more
europepmc   +3 more sources

A Systematic Review and Model-Based Meta-Analysis of Pegylated-Interferon-α-Induced HBsAg Loss in Chronic Hepatitis B Virus Infection. [PDF]

CPT Pharmacometrics Syst Pharmacol
Hanan NJ, Zierhut ML, Nader A, Mahajan A, Kaur A, Kumar K, Dixon SA, Das J, Magee M, Theodore D, Gielen V.   +10 more
europepmc   +3 more sources

Predicting loss of hepatitis B surface antigen and evaluating the durability of functional cure induced by pegylated interferon alpha: insights from a real-world study. [PDF]

PeerJ
Xu X, Huang JQ, Huang S.
europepmc   +3 more sources

Interferon-λ treatment accelerates SARS-CoV-2 clearance despite age-related delays in the induction of T cell immunity

Nature Communications, 2022
The interferon response is a critical component response to SARS-CoV-2 infection and prior studies have established a role for the administration of PEGylated interferon-lambda1 and its impact on viral clearance.
Deanna M. Santer, Daniel Li, Yanal Ghosheh, Muhammad Atif Zahoor, Dhanvi Prajapati, Bettina E. Hansen, D. Lorne J. Tyrrell, Jordan J. Feld, Adam J. Gehring   +8 more
doaj   +1 more source

Cost-effectiveness of pegylated interferon and ribavirin for patients with chronic hepatitis C treated in routine clinical practice. [PDF]

, 2009
OBJECTIVES: This study assesses whether pegylated interferon and ribavirin is cost-effective compared with no antiviral treatment provided in routine clinical practice, for different patient subgroups.
Grishchenko, Marina, Sweeting, Michael J, Thomson, Brian J, Irving, William L, Ryder, Stephen D, Grieve, Richard D, Trent HCV Study Group, De Angelis, Daniela   +7 more
core   +1 more source

Pegylated interferon-α-2b add-on therapy to renal function for chronic hepatitis B patients who were treated with tenofovir disoproxil fumarate: a retrospective real-world study. [PDF]

Virol J
Wang TB, Li AH, Zhuo Y, Wu HJ, Yue MQ, Wang YP, Wang XH.   +6 more
europepmc   +2 more sources